Core Laboratories/$CLB

CLB falls after reporting Q2 revenue flat year-over-year and issuing Q3 guidance calling for essentially flat sequential revenue, which disappointed investors.
9 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Core Laboratories

Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.

Ticker

$CLB
Sector

Primary listing

NYSE

Industry

Energy Equipment and Services

Employees

3,400

CLB Metrics

BasicAdvanced
$626M
21.54
$0.62
1.41
$0.04
0.30%

What the Analysts think about CLB

Analyst ratings (Buy, Hold, Sell) for Core Laboratories stock.

Bulls say / Bears say

Core Laboratories achieved a significant reduction in net debt by $42 million in 2024, lowering the leverage ratio to 1.31, the lowest in over eight years, indicating improved financial health and potential for future growth. (prnewswire.com)
The company reported a 200% year-over-year improvement in free cash flow for 2024, reaching $43.4 million, reflecting enhanced profitability and efficient working capital management. (prnewswire.com)
Core Laboratories expanded its proprietary HELIOS™ product line in 2023, offering advanced solutions for plug and abandonment operations, which could drive future revenue growth. (prnewswire.com)
The company's Production Enhancement segment experienced a 7% sequential revenue decline in Q4 2024, indicating potential challenges in maintaining consistent growth. (nasdaq.com)
Geopolitical factors and sanctions have produced headwinds to revenue growth and operating margins for the Reservoir Description segment, potentially impacting future performance. (nasdaq.com)
Core Laboratories' operating income decreased by 15.3% in Q2 2024 compared to the same quarter in 2023, suggesting potential profitability concerns. (apextraderfunding.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

CLB Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CLB Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CLB

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

Aug4
Core Laboratories
Dividend·Ex-dividend
Aug25
Core Laboratories
Dividend·Payment
$0.01Per share
FAQs